ADMA Q2 2021 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+129.0% YoY

Gross Profit

-$1M-5.6% margin

Operating Income

-$16M-87.4% margin

Net Income

-$19M-106.0% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+11.1%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$37M

Stock-Based Comp.

$805,189

Balance Sheet

Total Assets

$233M

Total Liabilities

$121M

Stockholders' Equity

$112M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$8M	+129.0%
Gross Profit	-$1M	-$6M	+82.4%
Operating Income	-$16M	-$17M	+9.0%
Net Income	-$19M	-$20M	+6.3%

Revenue Segments

Product Revenue

$18M100%

License Revenue

$35,7090%